A Problem-Solving Intervention for Women With Suicidal Ideation During Postnatal Period in Pakistan
Launched by PAKISTAN INSTITUTE OF LIVING AND LEARNING · May 1, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a special program designed to help women who are feeling very sad or hopeless after having a baby, which is often called postnatal depression. The study is focused on women in Pakistan who may have thoughts of suicide during this challenging time. Researchers want to see if this program, called CMAP-SI, can be adapted to fit the cultural needs of these women and whether it is helpful and acceptable to them. They will also explore how the program affects their thoughts about suicide.
To be part of this study, women must be between 16 and 44 years old, have a baby who is between 0 and 30 months old, and live in the area where the study is taking place. It’s important that they are able to understand and agree to participate in the study. Participants will not be in need of hospitalization for mental health issues. If you join, you can expect to receive support aimed at reducing feelings of hopelessness and learn more about your own experiences.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. 16 to 44-year-old mothers with children 0 - 30 months old
- • 2. Residents of the trial site catchments area
- • 3. Able to provide informed consent
- • 4. Presenting with suicidal ideation as measured by the Beck Suicidal Ideation Scale (BSSI) (must score 1 or 2 on item 4 and 5)
- • 5. Not requiring in-patient psychiatric treatment.
- Exclusion Criteria:
- • We will exclude mothers with any physical or psychiatric condition severe enough to prevent study participation.
About Pakistan Institute Of Living And Learning
The Pakistan Institute of Living and Learning (PILL) is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and evidence-based practices. With a focus on improving mental health and overall well-being, PILL conducts rigorous clinical trials that aim to evaluate new treatments and therapeutic approaches. The institute collaborates with a diverse range of stakeholders, including healthcare professionals, researchers, and community organizations, to ensure the highest standards of ethical conduct and scientific integrity in its studies. PILL is committed to translating research findings into practical solutions that enhance the quality of life for individuals and communities in Pakistan and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rawalpindi, Punjab, Pakistan
Patients applied
Trial Officials
Nasim Chaudhry, MD
Principal Investigator
Pakistan Institute of Living and Learning
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported